Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Soliris – Treatment for PNH and aHUS

Eculizumab adheres to the C5 complement protein and blocks it, thereby preventing its attack on the RBCs. Image courtesy of Pietro Roversi.

Go Top